amifostine anhydrous has been researched along with Nervous System Diseases in 10 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
Nervous System Diseases: Diseases of the central and peripheral nervous system. This includes disorders of the brain, spinal cord, cranial nerves, peripheral nerves, nerve roots, autonomic nervous system, neuromuscular junction, and muscle.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ninety ovarian cancer patients were randomized to receive standard paclitaxel + carboplatin without (PC) or preceded by amifostine 740 mg/m(2) (PC + A)." | 2.71 | A randomized phase II study of paclitaxel with carboplatin +/- amifostine as first line treatment in advanced ovarian carcinoma. ( Boezen, HM; Bos, AM; de Graaf, H; de Swart, CA; De Vos, FY; de Vries, EG; Schaapveld, M; van der Zee, AG; Willemse, PH, 2005) |
| " Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with cisplatin (e." | 2.70 | A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188). ( Abeloff, MD; Glover, DJ; Gradishar, WJ; Moore, MR; Neuberg, DS; Piel, I; Stephenson, P; Windschitl, HE, 2001) |
| " It was shown that this compound can protect normal cells from the toxic effects of ionizing radiation and chemotheraphy without affecting the efficacy of the therapy." | 2.39 | [Clinical use of Amifostine (WR-2721) as a preparation protecting healthy tissues from the cytotoxic effects of chemotherapy and radiation therapy]. ( Chomiczewski, K; Jabłońska, H; Wrembel-Wargocka, J, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 6 (60.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kanat, O | 1 |
| Evrensel, T | 1 |
| Baran, I | 1 |
| Coskun, H | 1 |
| Zarifoglu, M | 1 |
| Turan, OF | 1 |
| Kurt, E | 1 |
| Demiray, M | 1 |
| Gonullu, G | 1 |
| Manavoglu, O | 1 |
| De Vos, FY | 1 |
| Bos, AM | 1 |
| Schaapveld, M | 1 |
| de Swart, CA | 1 |
| de Graaf, H | 1 |
| van der Zee, AG | 1 |
| Boezen, HM | 1 |
| de Vries, EG | 1 |
| Willemse, PH | 1 |
| Treskes, M | 1 |
| van der Vijgh, WJ | 1 |
| Wrembel-Wargocka, J | 1 |
| Jabłońska, H | 1 |
| Chomiczewski, K | 1 |
| Selvaggi, G | 1 |
| Belani, CP | 1 |
| DiPaola, RS | 1 |
| Schuchter, L | 1 |
| Gradishar, WJ | 1 |
| Stephenson, P | 1 |
| Glover, DJ | 2 |
| Neuberg, DS | 1 |
| Moore, MR | 1 |
| Windschitl, HE | 1 |
| Piel, I | 1 |
| Abeloff, MD | 1 |
| Hamers, F | 1 |
| Neijt, J | 1 |
| Gispen, W | 1 |
| Tognella, S | 1 |
| Mollman, JE | 1 |
| Hogan, WM | 1 |
| Furman, RE | 1 |
5 reviews available for amifostine anhydrous and Nervous System Diseases
| Article | Year |
|---|---|
WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach.
Topics: Amifostine; Animals; Bone Marrow Diseases; Carboplatin; Cisplatin; Ear Diseases; Gastrointestinal Di | 1993 |
[Clinical use of Amifostine (WR-2721) as a preparation protecting healthy tissues from the cytotoxic effects of chemotherapy and radiation therapy].
Topics: Amifostine; Antineoplastic Agents; Hematologic Diseases; Humans; Kidney Diseases; Neoplasms; Nervous | 1996 |
Carboplatin and paclitaxel in non-small cell lung cancer: the role of amifostine.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carboplatin; Carci | 1999 |
Neurologic protection by amifostine.
Topics: Amifostine; Antineoplastic Agents; Clinical Trials as Topic; Cytoprotection; Humans; Nervous System; | 1999 |
Pharmacological interventions to reduce platinum-induced toxicity.
Topics: Adrenocorticotropic Hormone; Amifostine; Cisplatin; Ditiocarb; Fluid Therapy; Glutathione; Hematolog | 1990 |
3 trials available for amifostine anhydrous and Nervous System Diseases
| Article | Year |
|---|---|
Protective effect of amifostine against toxicity of paclitaxel and carboplatin in non-small cell lung cancer: a single center randomized study.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell L | 2003 |
A randomized phase II study of paclitaxel with carboplatin +/- amifostine as first line treatment in advanced ovarian carcinoma.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free S | 2005 |
A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).
Topics: Adult; Aged; Amifostine; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Disease Progression; Dr | 2001 |
2 other studies available for amifostine anhydrous and Nervous System Diseases
| Article | Year |
|---|---|
Protection of cisplatin-induced neuropathy: recent developments.
Topics: Adrenocorticotropic Hormone; Amifostine; Anticonvulsants; Cisplatin; Female; Glutathione; Humans; Ne | 1992 |
Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721.
Topics: Amifostine; Cisplatin; Drug Administration Schedule; Humans; Nervous System Diseases; Neural Conduct | 1988 |